LifeSci Capital analyst Charles Zhu maintained a Buy rating on Molecular Partners today and set a price target of $12.00.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Zhu is a 5-star analyst with an average return of 26.8% and a 64.55% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Revolution Medicines, Kura Oncology, and Immunome.
In a report released on July 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $13.00 price target.
Based on Molecular Partners’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $13.14 million. In comparison, last year the company had a GAAP net loss of $18.66 million
